All articles by Phillip Broadwith – Page 19
-
Business
US blocks imports from fourth Ranbaxy plant
FDA bans import of active ingredients from factory in Toansa, India
-
Business
Novartis and DSM trim jobs
Novartis to close US manufacturing site, both companies restructuring Swiss operations
-
Business
Plug and play redox enzymes
Technology profile: HydRegen is making cofactor-dependent catalysis cleaner
-
Business
US chemical spill contaminates water supplies
Life beginning to return to normal for locals after being without potable water for several days
-
Business
Novartis in the spotlight in mis-selling investigations
Crackdown on pharma marketing continues with US and Japanese cases
-
Business
Deadly explosion at Japanese silicon plant
Five killed and several more injured at Mitsubishi Materials site
-
Business
Thermo Fisher to sell three analytical divisions to GE Healthcare
Deal will help the firm complete its ongoing takeover of Life Technologies
-
Review
What a wonderful world: one man’s attempt to explain the big stuff
Don’t know much about a science book
-
Business
Lanzatech expands waste-to-chemicals range
Partnership with Evonik will see gas-guzzling microbes make polymer precursors
-
Business
Merck KGaA snaps up electronic materials specialist
Firm looks to bolster R&D by acquiring AZ Electronic Materials
-
Business
Nike eliminates water at new Taiwanese dyeing plant
ColorDry process uses supercritical CO2 to reduce waste and cut costs
-
Business
New wave of hepatitis C drugs hits US shore
J&J’s once-daily drug approved by FDA, but rivals are hot on its heels
-
Business
Regulator cracks down on 23andMe
Personal genetic profiler ordered to stop selling DNA test kits
-
Business
Pfizer teams up with GSK in cancer drug trial
Two companies will collaborate to develop a combination therapy for melanoma
-
Business
DSM to spin out pharma unit
Firm will combine with Patheon to provide manufacturing services
-
Business
Rapid DNA sequencing cleared for the clinic
Illumina’s ‘next-generation’ MiSeqDx platform gets US approval
-
Business
Novartis sells off blood diagnostics division
$1.7bn deal reinforces firm’s focus on core pharmaceuticals
-
Business
Fracking risks are manageable, says UK industry body
Environmental impact of shale gas exploration should be minimal with proper oversight